07:00 , Jul 7, 2008 |  BioCentury  |  Finance

Ebb & Flow

Fewer than one-fifth of the 660 or so VCs queried by the National Venture Capital Association and Thomson Reuters expect the IPO window to re-open this year. That’s according to a survey of NVCA’s membership on...
00:59 , Jul 3, 2008 |  BC Extra  |  Financial News

MiddleBrook falls on financing plans

MiddleBrook (NASDAQ:MBRK) fell $1.55 (50%) to $1.52 on Wednesday after announcing an agreement with Equity Group Investments (EGI) to raise $100 million. EGI will purchase 30.3 million shares at $3.30, which is a 7% premium...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

MiddleBrook infectious news

MiddleBrook (formerly Advancis Pharmaceutical Corp.) retained Morgan Stanley and Pacific Growth Equities LLC to seek strategic alternatives, including partnering its products or selling part or all of the company. The company originally said it...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Clinical News

Moxatag amoxicillin pulsys regulatory update

FDA approved an NDA from MiddleBrook (formerly Advancis Pharmaceutical Corp.) for 775 mg Moxotag extended-release amoxicillin tablets to treat patients aged 12 and up with pharyngitis/tonsillitis secondary to Streptococcus pyogenes infection (strep throat). The...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Company News

MiddleBrook, Deerfield Management Company L.P. deal

Healthcare investment fund Deerfield acquired MBRK's Keflex cephalexin business, excluding Keflex Pulsys, for $7.5 million up front. MBRK has an option to reacquire the assets for $11 million. If MBRK's Amoxicillin Pulsys receives...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Advancis infectious news

AVNC changed its name to MiddleBrook Pharmaceuticals Inc. and its ticker to MBRK. Advancis Pharmaceutical Corp. (AVNC), Germantown, Md.   Business: Infectious   ...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

Keflex Pulsys: Phase III start

MBRK (formerly Advancis Pharmaceutical Corp.) will begin a double-blind, non-inferiority Phase III trial in >=600 patients to compare 1,200 mg Keflex PULSYS once daily vs. 250 mg of Keflex cephalexin 4 times daily for...
07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

Amoxicillin Pulsys regulatory update

FDA accepted for filing an NDA for once-daily Amoxicillin Pulsys to treat adolescents and adults with pharyngitis/tonsillitis. The PDUFA date is Jan. 23, 2008. In March, AVNC resubmitted the NDA under section 505(b)(2) of the...
01:05 , May 23, 2007 |  BC Extra  |  Company News

FDA accepts Amoxicillin Pulsys NDA

Advancis (AVNC) gained $0.37 (14%) to $3.10 on Tuesday after FDA accepted for filing an NDA for once-daily Amoxicillin Pulsys to treat adolescents and adults with pharyngitis/tonsillitis. The PDUFA date is Jan. 23, 2008. AVNC...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Company News

Advancis board of directors update

Advancis Pharmaceutical Corp. (AVNC), Germantown, Md.   Business: Infectious   Appointed: Martin Vogelbaum, a partner at Rho Ventures   ...